ACOD1 and neoplasm: We never detected Irg1 expression in tumor cells, and if Irg1 expression is relatively Mφ specific, then targeting Irg1 levels in the peritoneum may be a means to regulate pResMφ-derived ROS without eliciting some of the side effects associated with systemic ROS inhibition.